BioNTech SE Website

BioNTech SE

NasdaqGS-BNTX

Basic

  • Market Cap

    $20.43B

  • EV

    $3,787.76M

  • Shares Out

    241.32M

  • Revenue

    €2,729.6M

  • Employees

    6,133

Margins

  • Gross

    79.38%

  • EBITDA

    -6.11%

  • Operating

    -11.43%

  • Pre-Tax

    5.37%

  • Net

    4.14%

  • FCF

    200.33%

Returns (5Yr Avg)

  • ROA

    32.27%

  • ROTA

    38.33%

  • ROE

    37.37%

  • ROCE

    58.75%

  • ROIC

    41.13%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $112.05

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    €15.67B

  • Net Debt

    -€15.43B

  • Debt/Equity

    0.01

  • EBIT/Interest

    -27.37

Growth (CAGR)

  • Rev 3Yr

    2.93%

  • Rev 5Yr

    83.27%

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    -53.61%

  • Dil EPS 5Yr

    3.09%

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    -15.31%

  • EBITDA Fwd 2Yr

    -97.64%

  • EPS Fwd 2Yr

    -93.8%

  • EPS LT Growth Est

    2%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

108.6

482.3

18,976.7

17,310.6

3,819

2,729.6

Total Revenues % Chg.

—

-14.9%

344.1%

3,834.6%

-8.8%

-77.9%

-77.7%

Cost of Goods Sold, Total

17.4

59.3

2,911.5

2,995

599.8

562.9

Gross Profit

91.2

423

16,065.2

14,315.6

3,219.2

2,166.7

Selling General & Admin Expenses, Total

48.7

108.5

327.2

541.2

557.7

566.3

R&D Expenses

226.5

645

949.2

1,537

1,783.1

1,956.6

Other Operating Expenses

-2.5

-9.1

79.5

320.5

-91.2

-44.2

Other Operating Expenses, Total

272.7

744.4

1,355.9

2,398.7

2,249.6

2,478.7

Operating Income

-181.5

-321.4

14,709.3

11,916.9

969.6

-312

Interest Expense, Total

-1.7

-2

-27.3

-18.9

-7.9

-11.4

Interest And Investment Income

1.8

1.6

1.5

48.5

357.6

357.6

Net Interest Expenses

0.1

-0.4

-25.8

29.6

349.7

346.2

Income (Loss) On Equity Invest.

—

—

—

—

—

—

Currency Exchange Gains (Loss)

2.3

-42.6

512.5

792.4

-268

-101.4

Other Non Operating Income (Expenses)

-0.3

-20.4

-277.8

216.8

162

254.6

EBT, Excl. Unusual Items

-179.4

-384.8

14,918.2

12,955.7

1,213.3

187.4

Legal Settlements

—

—

—

—

-9

-3

-29.4

-43

Other Unusual Items

—

—

239

137.2

1.4

2.2

2.2

EBT, Incl. Unusual Items

-179.4

-145.8

15,046.4

12,954.1

1,186.1

146.6

Income Tax Expense

-0.2

-161

4,753.9

3,519.7

255.8

33.6

Earnings From Continuing Operations

-179.2

15.2

10,292.5

9,434.4

930.3

113

Minority Interest

0.1

—

—

—

—

—

Net Income

-179.1

15.2

10,292.5

9,434.4

930.3

113

Net Income to Common Incl Extra Items

-179.1

15.2

10,292.5

9,434.4

930.3

113

Net Income to Common Excl. Extra Items

-179.1

15.2

10,292.5

9,434.4

930.3

113

Total Shares Outstanding

226.8

241.5

242.5

243.2

237.7

237.7

Weighted Avg. Shares Outstanding

211.5

235.4

244

243.3

240.6

240.1

Weighted Avg. Shares Outstanding Dil

211.5

248.5

259.7

249.8

242.7

241.6

EPS

-0.8

0.1

42.2

38.8

3.9

0.5

EPS Diluted

-0.9

0.1

39.6

37.8

3.8

0.5

EBITDA

-152.3

-289

14,755.5

11,981.4

1,107.8

-166.9

Effective Tax Rate

0.1%

110.4%

31.6%

27.2%

21.6%

22.9%